Prior authorization & UM · Clinical NLP for PA / UM
Hindsait
Hindsait applies clinical NLP and document intelligence to prior authorization and utilization-management review for plans and related organizations. It is not a clinic-side portal automation product.
Strong fit
- Health plans, MACs, and UM teams reading unstructured charts for prior auth and medical necessity
- Groups that need audit-ready evidence matching against MCG, InterQual, or plan criteria
- Buyers measuring review minutes per case and first-pass determination consistency
Weak fit
- Small clinics that only need portal submission helpers for a handful of payers
- Buyers shopping a full claims clearinghouse or patient billing product
- Teams that will not keep clinicians in the loop for complex determinations
Bottom line
Hindsait earns a Recommend for payer and MAC utilization-management teams whose prior authorization and clinical review work still dies inside unstructured charts. Outcomes show up in shorter review times and more consistent criteria matching when clinical NLP feeds worksheets rather than free-text hunting. Product strength is healthcare-specific document intelligence for PA and UM, not a provider portal automation suite like Valer. Implementation needs UM ownership, guideline libraries, and PHI controls. Pricing is quote-based. Public size signals are small (LinkedIn-class headcount under 15; third-party revenue often cited under $10M), clearly under the hard cap. Score sits under Xsolis and Agadia on overall for a narrower NLP-and-review lane, above Rhyme on clinical depth.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Hindsait is a Hackensack-based clinical AI company founded in 2013. It turns unstructured medical records into structured evidence for prior authorization, utilization management, and related clinical review. Public materials cite production use at WPS Health and Gartner 2026 recognition in intelligent prior authorization.
It is not a provider portal-filling tool. Compare Xsolis or Agadia when the buyer wants a full payer UM suite, Careviso when lab and specialty submission workflows dominate, and Infinitus when the bottleneck is phone time with payors.
Score reflects solid clinical NLP depth with softer marks on price clarity and the change management required to land in production UM queues.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Hindsait | 7.0 | 6.7 |
| Xsolis | 7.8 | 7.3 |
| Agadia | 7.6 | 7.2 |
| Careviso | 7.6 | 7.3 |
| Develop Health | 7.0 | 6.8 |
| Infinitus | 7.7 | 7.4 |
| Rhyme | 6.5 | 6.3 |
Pricing
| Item | Detail |
|---|---|
| Model | Clinical intelligence platform packaging for PA, UM, and related review workflows; quote-based. |
| What usually drives cost | Case volume, modules (PA, UM, payment integrity), deployment (cloud vs on-prem), and professional services. |
| What to ask in diligence | Cost per review or annual platform fee at your monthly PA/UM volume, with human-in-the-loop coverage defined. |
| Published pricing | Public list price: not published. Expect volume-based platform pricing. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Hindsait to function | |
| Named prior-auth or access owner with authority to change submission workflows | Software without owners becomes shelfware. |
| Baseline authorization turnaround and denial or abandonment rates captured | You cannot prove value without a before number. |
| EHR, ordering, or practice-management feed inventory documented | Missing feeds recreate portal swivel-chair work. |
| Staffing plan for exception queues after go-live | Unowned exceptions age into delayed care. |
| Top payers and service lines by PA volume listed | Generic configs miss your real bottlenecks. |
| What will maximize your value | |
| Track median days-to-authorization weekly for 90 days | Login counts are not outcomes. |
| Start with one specialty or lab channel first | Narrow wins beat empty enterprise banners. |
| Retire duplicate spreadsheet trackers after a parallel month | Dual entry doubles cost. |
| Review stalled exceptions in a standing huddle | Silent aging hides failure. |
| Publish a monthly access digest to clinical and revenue leaders | Hidden delays surprise everyone. |
| Deal-breakers | |
| Nobody will own prior-auth exception queues. | |
| You refuse the interface or enrollment work the product needs. | |
| You expect a full EHR replacement from a PA tool. | |
| Leadership will not measure authorization turnaround. | |
| Compliance blocks the data path required for submissions. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope & baseline | 2-4 weeks - Metrics, payer mix, feed inventory. |
| 2 | Configure | 4-10 weeks - Rules, templates, interfaces; test cases. |
| 3 | Pilot | 2-6 weeks - One specialty or site; exception playbook. |
| 4 | Scale | 1-3 months - Add payers/sites; retire shadow trackers. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.